Try Claude
Lead FinderFind & enrich companies and people
AI Tools for Clinical Trial Managers
AI tools that help clinical trial managers search trial registries, look up drug and regulatory information, monitor economic calendars for submission deadlines, compile trial landscape reports, and manage study operations.
Get started for free
Works in Chat, Cowork and Code
NctRegimenSponsor
NCT04048187Pembrolizumab + carboplatin/pemetrexedMerck
NCT04380012Nivolumab + ipilimumab + chemoBMS
NCT04631120Atezolizumab + carboplatin/nab-paclitaxelRoche
9 active Phase 3 trials found
Clinical trial registry search
Search ClinicalTrials.gov comprehensively by condition, intervention, phase, sponsor, status, and geographic region. Build competitive intelligence landscapes, identify recruiting sites for feasibility assessments, and monitor study status changes.
Find all active Phase 2 and 3 trials studying CAR-T therapies in relapsed/refractory multiple myeloma. Include sponsor, NCT number, target antigen, and current enrollment status.
Found 18 trials. Active Phase 3: ide-cel (bb2121) long-term follow-up, cilta-cel CARTITUDE-4 OS follow-up. Phase 2: 4 BCMA-targeted programs, 2 GPRC5D-targeted, 1 CD38/BCMA bispecific CAR-T. Includes NCT numbers, sponsor, site count, and estimated completion dates.
ToolRouter search_trials
NctTargetSponsor
NCT03361748BCMA (ide-cel)BMS/2seventy
NCT04133636BCMA (cilta-cel)J&J
NCT05066984GPRC5DJanssen
NCT04196491BCMA/CD38 bispecificPfizer
18 trials found · Phase 2 and 3
Drug and comparator information lookup
Pull FDA labeling data for investigational comparators, standard-of-care regimens, and approved drugs in the disease area. Access dosing, administration requirements, adverse event profiles, and contraindications for protocol development and site training materials.
Get FDA labeling for carboplatin and paclitaxel combination therapy including dosing calculations (AUC and mg/m²), premedication requirements, and major toxicities for protocol background.
Carboplatin: dosed by Calvert formula (AUC 5-6 mg/mL·min, Cockcroft-Gault CrCl). Paclitaxel: 175 mg/m² over 3h q3w. Premedications: dexamethasone 20mg PO x2, diphenhydramine 50mg IV, H2 blocker. Key toxicities: myelosuppression (nadir Day 8-12), peripheral neuropathy, alopecia, hypersensitivity reactions.
ToolRouter get_drug
Carboplatin Dosing
Calvert formula: AUC 5–6 mg/mL·min (Cockcroft-Gault CrCl)
Paclitaxel Dosing
175 mg/m² over 3h q3w
Premedications
Dexamethasone 20mg PO ×2 + diphenhydramine 50mg IV + H2 blocker
Key Toxicities
Myelosuppression (nadir D8–12), peripheral neuropathy, alopecia
Hypersensitivity
Paclitaxel HSR risk — infusion reactions; monitor closely
Regulatory and conference deadline tracking
Monitor FDA PDUFA action dates, EMA opinion dates, ICH guideline comment windows, and major clinical conference abstract submission deadlines. Keep trial timelines and publication strategies on track.
What are the upcoming FDA PDUFA dates and major oncology conference abstract submission deadlines over the next 90 days?
Found 9 events: 3 PDUFA dates (hematology and solid tumor NDAs), ASCO abstract submission deadline (Jan 18), ESMO abstract deadline (Feb 14), ASH abstract deadline (June 7), FDA Oncologic Drugs Advisory Committee meeting (March 12). Includes drug names and conference details.
ToolRouter search_events
Jan 18
ASCO Abstract Deadline
Feb 14
ESMO Abstract Deadline
Mar 12
FDA Oncologic Drugs AdCom
Apr 3
PDUFA Date — Hematology NDA
Apr 18
PDUFA Date — Solid Tumor BLA
Clinical operations and methods literature
Search the clinical operations and methodology literature for best practices on decentralized trials, eConsent, risk-based monitoring, data management, and patient recruitment strategies. Stay current with Good Clinical Practice updates.
Find papers on risk-based quality management (RBQM) implementation in Phase 2-3 oncology trials — models used, monitoring frequency reduction achieved, and FDA/EMA acceptance.
Found 14 papers. Key results: RBQM with central monitoring reduced on-site visits by 30-50% while maintaining data quality in 3 industry studies; TransCelerate framework adoption highlighted; both FDA and EMA have issued supportive guidance. Includes journal, DOI, and trial size.
ToolRouter search_papers
Papers Found
14 publications on RBQM implementation
Site Visit Reduction
30–50% fewer on-site visits while maintaining data quality
TransCelerate Framework
RBQM adoption model widely referenced — 3 papers
FDA Acceptance
FDA issued supportive guidance; EMA aligned
Top Finding
Central statistical monitoring detects 80%+ of data issues remotely
Trial feasibility and landscape research
Compile comprehensive intelligence reports on any disease area or therapeutic category before opening a new study. Understand the competitive landscape, patient population size, and regulatory precedents for key design elements.
Compile a feasibility research report for a Phase 2 trial in frontline metastatic gastric cancer — current standard of care, enrolled trial endpoints, tumor biomarker use, and patient population estimates.
Compiled 22-source report: Current SoC — pembrolizumab + fluoropyrimidine + platinum (KEYNOTE-590); ToGA-defined HER2+ subset (15-20% of patients) addresses separately; PD-L1 CPS ≥1 and CLDN18.2 as emerging biomarker segments; global annual incidence ~1.1M; competitive trials (RATIONALE-305, SPOTLIGHT) set endpoint precedents for PFS and OS.
ToolRouter research
Current SoC
Pembrolizumab + fluoropyrimidine + platinum (KEYNOTE-590)
HER2+ Subset
15–20% of patients — addressed by ToGA-defined regimen
Emerging Biomarkers
PD-L1 CPS ≥1 and CLDN18.2 as stratification targets
Global Incidence
~1.1M annually; Asia-Pacific largest patient pool
Endpoint Precedents
PFS and OS from RATIONALE-305 and SPOTLIGHT trials
Clinical trial workflow and process diagrams
Generate labeled diagrams of trial schemas, randomization structures, dose escalation designs, and clinical operations workflows for protocols, site training, and investigator presentations.
Draw a 3+3 dose escalation design schema for a Phase 1 oncology trial showing cohort size, dose decision rules, DLT assessment window, and expansion criteria.
Generated 3+3 schema: cohort of 3 patients enrolled at each dose level → if 0/3 DLTs: escalate → if 1/3 DLTs: enroll 3 more → if ≤1/6 DLTs: escalate → if ≥2/6 DLTs: MTD exceeded. MTD = dose level below highest with ≥2/6 DLTs. Expansion cohort at RP2D shown separately.
ToolRouter render_diagram
Cohort 1
3 patients enrolled at starting dose level
DLT = 0/3
Escalate to next dose level
DLT = 1/3
Enroll 3 additional patients (expand to 6)
DLT ≤1/6
Escalate; if ≥2/6 DLTs: MTD exceeded
MTD Defined
Dose level below highest with ≥2/6 DLTs
RP2D
Expansion cohort opened at recommended Phase 2 dose
Ready-to-use prompts
Competitive trial search
Find all active Phase 3 trials in frontline advanced HCC (hepatocellular carcinoma) using immunotherapy combinations. Include sponsor, regimen, primary endpoint, and estimated completion date.
Drug comparator lookup
Get FDA labeling for docetaxel including dosing, premedications, key toxicity profile, and labeled indications for use as a comparator arm reference in a lung cancer protocol.
Regulatory deadline tracking
Find upcoming FDA Advisory Committee meetings for oncology drugs, PDUFA action dates, and EMA CHMP opinion sessions in the next 60 days.
Operations literature search
Find papers on electronic patient-reported outcomes (ePRO) implementation in oncology clinical trials — validation approaches, compliance rates, and regulatory acceptance published since 2020.
Trial design research
Research current FDA guidance and industry experience with seamless Phase 2/3 adaptive designs — examples, success rates, and agency acceptance criteria.
Trial schema diagram
Draw a trial schema diagram for a 2-arm randomized Phase 2 trial showing screening, randomization (1:1), treatment periods, and primary endpoint assessment timepoints.
Find clinical research organizations
Find clinical research organizations (CROs) and contract research sites in Eastern Europe and Latin America specializing in oncology Phase 2-3 trials with experience in immuno-oncology studies.
Regulatory guidance research
Compile a summary of FDA and EMA guidance on co-primary endpoint strategies and multiplicity correction in oncology randomized trials issued since 2018.
Tools to power your best work
Academic ResearchSearch papers, authors, citations
Deep ResearchAI research reports with citations
Drug InformationDrug info: recalls & side effects
Diagram GeneratorRender Mermaid, PlantUML & more
Economic CalendarEarnings, IPOs, FOMC & events
Clinical TrialsClinical trials & drug safety data
165+ tools.
One conversation.
Everything clinical trial managers need from AI, connected to the assistant you already use. No extra apps, no switching tabs.
Protocol development intelligence package
Before writing a protocol, build a comprehensive intelligence package covering the competitive landscape, standard of care, and regulatory precedents.
Site training preparation
Prepare site training materials by reviewing drug information and regulatory guidance relevant to study operations.
Regulatory submission timeline planning
Build a regulatory timeline by tracking PDUFA dates, advisory committee meetings, and key FDA guidance windows.
Frequently Asked Questions
How current is ClinicalTrials.gov data in the Clinical Trials tool?
Clinical Trials pulls directly from ClinicalTrials.gov, which is updated as sponsors submit amendments, status changes, and results. Data is typically within days of the official registry update.
Can Drug Information be used to verify eligibility criteria against approved labeling?
Drug Information retrieves approved drug labeling including contraindications, warnings, and precautions, which directly inform exclusion criteria development. It is a useful reference for protocol writers aligning eligibility with known drug risks.
Does the Economic Calendar cover EMA and Health Canada regulatory events?
Economic Calendar covers major regulatory agency events including FDA, EMA CHMP opinion dates, and select other agency meetings. Coverage of Health Canada and PMDA is more limited — supplementary checks on those agency websites are recommended for comprehensive global regulatory tracking.
Can Academic Research find ICH and GCP guideline publications?
ICH guidelines published in indexed journals and regulatory journals are retrievable via Academic Research. Official ICH, FDA, and EMA guideline documents themselves are better sourced via Deep Research, which can locate current documents on official agency websites.
Is there a way to track patient enrollment rates and feasibility indicators for sites?
ClinicalTrials.gov includes estimated enrollment, actual enrollment, and study status updates, all accessible through the Clinical Trials tool. Detailed site-level enrollment performance data typically requires access to sponsor or CRO operational systems.
Give your AI superpowers.
Get started for free
Works in Chat, Cowork and Code